Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Special Report: Animal Pharm African Swine Fever 2020
12 February 2020
Author: Ingentium Limited | Number of pages: 111 | PDF
Report
African Swine Fever (ASF) is currently the most important threat
to the pig industry worldwide. ASF is a highly contagious viral
disease of domestic and wild pigs, that has become a serious global
threat to the pig sector and related industries. It is listed by
the World Organization for Animal Health (OIE) as a notifiable
disease. ASF is not a zoonotic disease and thus does not pose a
risk to public health.
Until 2007, outbreaks were limited to Africa and the
Mediterranean island of Sardinia. In 2007 the disease entered
Georgia and has been spreading into Europe and now Asia where it
has been infecting both domestic and wild pigs. It has since gone
on to rapidly spread across most of Asia, leaving a devastating
trail in China. In 2018, China reported the first case of ASF.
China has the world's largest pig population, and has since seen
its pig population reduced by half. This has led to supply and
demand shortages not only in China but globally. The disease is now
present in Greece and spreading across Indonesia. The report is
completely up to date on the global ASF trajectory as of
mid-February 2020.
There is currently no effective vaccine and no treatment for
ASF. Control is based on containing the outbreaks through
biosecurity measures and the stamping out of infected and
in-contact animals. This report explores the likely development of
treatments and their costs going forward. A prompt diagnosis is
critical to restrain and control the disease. The Diagnostics
Review section provides a summary of virus detection tests and
antibody detection tests.
It is estimated that the value of an ASF Asian market vaccine
over a period of four years is likely be in the region of US$112
million. There has undoubtedly been an increase in patenting
activity with respect to ASF related technologies filed globally
over the past 10 years. Bearing in mind that patent filing data may
not be fully disclosed for applications filed in 2019, the average
increase of filings year-on-year appears to be circa 13%. A mixture
of both public and private-sector organisations appears to be
applicants/assignees (the owners) on ASF-related patents. Notable
patent filings and related transactions are discussed in further
detail within the report.
For contents pages, executive summary and sample pages:
